Beckley Psytech

Atai Life Sciences (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on mental health innovation, announced its third-quarter 2024 financial results Wednesday as well as updates on its clinical and corporate strategies. With notable advancements in its investigational programs, the...

The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic formulation of psilocin benzoate to treat major depressive disorder (MDD). Psilocin is the active metabolite...

Private psychedelics medicine company Beckley Psytech confirmed Monday that the first patient has been dosed in a new research study investigating the neurophysiological effects of BPL-003, the company's novel synthetic intranasal formulation of 5-MeO-DMT (also known as mebufotenin), on the human...

Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary...

Clinical-stage private biotech company Beckley Psytech Ltd has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment.  CEO ‍Cosmo Feilding Mellen said the company’...

Private clinical-stage psychedelics biotech Beckley Psytech Ltd. has initiated a Phase 2a proof-of-concept study on BPL-003, its proprietary intranasal formulation of synthetic 5-MeO-DMT for Treatment-Resistant Depression (TRD.) Founded in 2019 and yet based on more than two decades of...

Private clinical-stage psychedelics biotech Beckley Psytech announced it has successfully completed a Phase 1 clinical study on BPL-003, its patent-protected, synthetic intranasal formulation of 5-MeO-DMT under development for Treatment-Resistant Depression (TRD) and Alcohol Use Disorder (AUD.)...

Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets.  Eleusis CEO Shlomi Raz will become Beckley’...

Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund. The oversubscribed fund is positioned to have a transformative impact on the field of mental health by funding a diverse portfolio...

The Week In Psychedelics Last week saw some interesting developments from two of the largest publicly-traded companies in the psychedelics space: MindMed and Atai Life Sciences. MindMed announced that the FDA has allowed it to advance with a phase 2 trial on LSD, the first commercial trial on the...

Beckley Psytech, a private company in the psychedelics space, announced that it has begun training psychotherapists for a Phase 2 clinical trial with 5-MeO-DMT, a strong and fast-acting psychedelic compound naturally produced by the Sonoran Desert Toad. The company launched a program to study 5-MeO...

Beckley Psytech Closes $80 Million Series B Beckley Psytech announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and 5-MeO-DMT research into neuropsychiatric disorders. The financing was upsized from an...

Beckley Psytech, an Oxford-based psychedelics research company, announced the closing of a £58 million ($80 million) Series B raise, which will be used to further finance the company’s psilocybin and 5-MeO-DMT research into neuropsychiatric disorders. The financing was upsized from an...

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm. What in 2019 was merely a buzzword for investors became a full-fledged industry boasting over 25...

5-MeO-DMT is a potent and fast-acting psychedelic, which is naturally produced by the Sonoran Desert toad as well as some species of plants. Its short duration –from 20 minutes to one hour– is giving hope to researchers and executives in the psychedelics space who are seeking ...